Cite
HARVARD Citation
Khushalani, N. et al. (2022). Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer. 10 (11), p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Khushalani, N. et al. (2022). Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. Journal for immunotherapy of cancer. 10 (11), p. . [Online].